Diagnosis, management and monitoring of patients with Pompe disease in the UK Authors: Jordi Díaz-Manera, Alexander Broomfield, James Davison, Patrick Deegan, Rachel Gould, Tarekegn Geberhiwot, Meredith K James, James B Lilleker, Reena Sharma Published: 2025 ABSTRACT AbstractPompe disease is a rare, inherited metabolic disorder characterised by lysosomal acid alpha-glucosidase deficiency. The disease is classified into infantile-onset and late-onset forms and is treated with enzyme replacement therapy. Currently, there are no standardised clinical management guidelines for Pompe disease in the UK.An expert panel of nine healthcare professionals with expertise in caring for patients with Pompe disease was convened. A review of the literature was performed for an overview of the available evidence and to identify gaps. This was used to develop survey questions for the steering committee to answer based on their clinical experience. Statements were drafted based on answers and voted on anonymously by the experts before being discussed during two meetings to reach consensus.Consensus was reached on how to diagnose Pompe disease in adult and paediatric patients, evaluations to assess disease progression and treatment effect and long-term management.These are the first UK-specific guidelines describing clinical management of Pompe disease.Keywords: METABOLIC DISEASE, MUSCLE DISEASE, HEALTH POLICY & PRACTICE Background Pompe disease overview Pompe disease is a rare autosomal recessive genetic disorder where biallelic pathogenic variants in GAA result in lysosomal enzyme acid alpha-glucosidase (GAA) deficiency.1 GAA has a cellular housekeeping function by degrading glycogen into glucose within the lysosome.2 In patients with Pompe disease, the accumulation of glycogen drives pathophysiology where accumulation principally in diverse muscle tissues gives rise to significant morbidity and mortality.3 Worldwide incidence varies by country and ethnicity and ranges from 2 in 100 000 to 1 in 17 000, with prevalence in the UK being approximately 1 in 40 000.4 5 The infantile form is rarer, with a worldwide incidence of 1 in 138 000.6 7 It is estimated that there are 35–40 children living with infantile-onset Pompe disease (IOPD) in the UK.6 Pompe disease is classified according to age of presentation. Disease severity varies according to the degree of residual GAA activity. Patients with IOPD have very low or absent GAA activity (<1% of normal levels), while patients with late-onset Pompe disease (LOPD) have 2%–40% of normal GAA activity.8 9 IOPD is more severe than LOPD and presents at birth or within the first few months of life, with a high risk of death in infancy if untreated.10 11 LOPD can occur in childhood or adulthood.10 Infants with IOPD typically present with hypotonia, generalised muscle weakness, feeding difficulties due to bulbar muscle weakness, failure to thrive and a combination of respiratory muscle insufficiency and cardiac failure.10 12 Cardiac manifestations include hypertrophic cardiomyopathy with the potential for cardiac failure and arrhythmias. ECG can show a short PR interval and high QRS complex voltage.8 10 13 Respiratory muscle weakness can progress to respiratory failure in children with IOPD. Moreover, respiratory distress in combination with progressive dysphagia leads to feeding difficulties, which can limit calorie intake. Consequently, these manifestations contribute to failure to thrive.14 15 Additionally, glycogen also accumulates in the central nervous system, potentially leading to cognitive decline.16 The heterogeneity of LOPD, the wide spectrum of symptom severity and slow progression, makes identifying the disease a complex process, which can lead to a delay in diagnosis.10 Clinical manifestations of LOPD typically occur after infancy and rarely include cardiomyopathy.17 Common symptoms are muscle weakness that usually starts affecting the pelvic and axial muscles and later on progresses to proximal muscles of the upper and lower limbs. Patients often develop respiratory muscle weakness that can present earlier after onset of symptoms and advance to respiratory failure.10 Diagnostic delays can also be from a lack of knowledge of disease presentation and natural history.13 Given the challenges of diagnosis and the delay in treatment initiation of Pompe disease, there is a need to optimise and standardise care pathways to improve patient outcomes, as delays in diagnosis postpone treatment initiation and any associated benefit. Moreover, the pathophysiology and progression of IOPD and LOPD warrant a careful, multidisciplinary approach to ensure patients receive optimum care.18 Various clinical specialties are required for symptom management, treatment administration and follow-up. While diagnostic algorithms have been published,19 20 there is a lack of uniform recommendations for clinical management and ongoing monitoring in the UK. The statements agreed through the consensus process described in this report are intended to provide clear guidance to clinicians to support diagnosis, monitoring and management of patients with IOPD or LOPD. Treatment considerations are beyond the scope of this article and therefore will not be discussed. The reader is invited to refer to other published work that outlines therapy criteria in further detail.21,23 Methods Steering committee selection The methodology that was used in this publication is summarised in online supplemental figure 1. The steering committee was formed of nine members representing seven different UK centres that provide care for adult and/or paediatric patients with Pompe disease. These were chosen due to their relative medical and research experience. The specialties of the physicians on the panel included neurology and metabolic medicine in addition to paediatric metabolic nursing and neuromuscular physiotherapy. Every effort was made to include a range of roles and specialities across multidisciplinary teams (MDTs). Literature search A literature search was performed of relevant articles published from August 2019 to August 2023, using PubMed. The search focused on three main themes: identification and diagnosis, multidisciplinary management and multidisciplinary monitoring. The aim was to survey the literature to address key questions on holistic clinical management of Pompe disease, covering identification and diagnosis, treatment considerations and ongoing respiratory, musculoskeletal, cardiological and health-related quality of life (HRQoL) monitoring. The questions and terms used for the search are described in online supplemental material 1al. A total of 784 articles were identified. These were filtered to exclude articles not in English and include clinical trials, meta-analyses, observational studies, reviews and systematic reviews. After the initial screening, 74 articles were reviewed for relevance. Subsequently, 56 articles were accepted for inclusion. A report summarising the evidence was prepared and reviewed by the experts (data not included). The information gathered in the literature review, and associated evidence gaps, were used to develop survey questions to enable the steering committee to share their views of the evidence base and best practice. The survey responses were then consolidated and used to develop consensus statements, with this process being overseen by the panel Chair. Statements were voted on anonymously with the options being ‘agree’, ‘agree with amends’ or ‘disagree’. The threshold for consensus was set at ≥75% ‘agree’ or ‘agree with amends’. Statements that did not reach consensus or with conflicting amends were discussed live at two virtual meetings. Results General principles There were 54 preliminary statements. Of those, there was consensus on 47 statements with or without minor amendments following the initial round of voting. Seven statements required further discussion, and virtual meetings were convened to see if they could be refined, reframed or combined with other statements to achieve consensus. During these meetings, consensus was reached on all statements, to produce the final, revised 35 statements included in boxes15. Test recommended for the diagnosis of Pompe disease An enzymatic assay of alpha-glucosidase activity should be conducted. Patients should be screened using DBS, followed by leucocytes for confirmation. The leucocyte assay is more sensitive and less prone to false negatives or false positives than DBS. The diagnosis of Pompe disease should be confirmed using genetic testing for GAA mutations. Adjunctive laboratory assessments to support a diagnosis could be performed and may include CK, urinary Hex4 or PAS-positive lymphocyte vacuoles. In the case of IOPD, cardiological examinations may support the diagnosis, when these identify hypertrophic cardiomyopathy and/or shortened PR interval. In the case of LOPD, additional investigations that may support a diagnosis include clinical examination, EMG, muscle MRI, ultrasound, respiratory studies and muscle biopsy. CK, creatine kinase; DBS, dried blood spot; EMG, electromyography; Hex4, glucotetrasaccharide; IOPD, infantile-onset Pompe disease; LOPD, late-onset Pompe disease; PAS, periodic acid-Schiff. Recommendations for improving patient reviews Where practical, patients can be offered a ‘one-stop shop’ clinic where most assessments can be carried out in as few visits as possible. If feasible, patient travel and fatigue can be minimised by reducing travel and offering suitable accommodation. For patients whose disease is stable, occasional virtual consultations can be offered in between face-to-face visits. Patient preferences in terms of hospital visit frequency and number of assessments per visit should be taken into consideration, alongside the minimum time needed to effectively monitor progress. Engagement with local and community services is critical (although dependent on capacity) to ensure ongoing care and facilitation of reviews at local centres, where feasible, including blood sample collection, lung function tests, local physiotherapist, pain management and palliative care input. Assessments being carried out by a consistent healthcare team can reduce observer variability. Apps that collect patient-reported outcomes should be evaluated and implemented where possible to reduce the burden of questionnaires and improve data collection, provided they meet NHS data protection and security safeguards. Wearable technologies can be useful for actigraphy. Remote spirometry can be suggested to patients if appropriate for their specific condition, with input from their healthcare team. The language used within statements, eg, “may”, “should” or “consider” indicates the strength of recommendation, based on overall assessment of the strength of the relevant evidence and recognition of the need to manage every patient based on their individual needs.24 Recommendations on initial diagnostic tests and laboratory assessments for patients with Pompe disease General diagnostic principles Early diagnosis can lead to a reduction in mortality in patients with IOPD and improved outcomes in patients with LOPD.15 IOPD can progress rapidly and result in death if not diagnosed and managed early.13 25 26 Timely diagnosis is, therefore, critical to improving clinical outcomes. Newborn screening, which has been established in certain countries, can help with early identification of patients with IOPD, though this is not conducted in the UK.27 28 In LOPD, the initial signs are not specific to Pompe disease and can be mistaken for other neuromuscular disorders, delaying diagnosis.29 The heterogeneity of LOPD and the wide spectrum of symptom severity present further diagnostic challenges.30 Suggested investigations when Pompe disease is suspected are outlined in box 1. Diagnostic tests A combination of enzymology, genetics and biomarker assessments is recommended for the initial diagnosis of Pompe disease. Measuring GAA activity using either dried blood spot or in leucocytes is often the first step on the diagnostic algorithm, which must be confirmed with genetic testing for mutations in GAA.8 18 31 The identification of pathogenic variants in both alleles of the GAA gene usually confirms the diagnosis, with extensive disease-specific databases available, such as https://www.pompevariantdatabase.nl/newly Identified mutations or variants of unknown significance, the identification of a low GAA activity in at least two different tissues, including leucocytes, skin fibroblasts or muscle, strongly supports the diagnosis of Pompe disease. Leucocytes, skin fibroblasts or muscle strongly support the diagnosis of Pompe disease. For LOPD, findings of other complementary tests, such as muscle biopsy, muscle MRI or electromyography (EMG), can support a diagnosis.9 14 Muscle MRI can identify a characteristic pattern of fatty replacement, and EMG findings like repetitive or myotonic discharges may be suggestive of Pompe disease. Notably, these tests are not specific to Pompe disease and require further confirmation.3032,34 Diagnostic considerations specific to IOPD IOPD should be considered in an infant that presents with severe generalised muscle weakness, hypotonia and cardiomegaly, which result from glycogen build-up.10 33 Hypertrophic cardiomyopathy, an early hallmark of IOPD, may be suspected clinically, or from observation of cardiomegaly on X-ray, and then confirmed by echocardiography.14 Urine analysis of tetrasaccharide, a glycogen metabolite, can be used as a confirmatory test to supplement an IOPD diagnosis.35 In the cases of diagnosed IOPD, it is important to determine the patient’s cross-reactive immunological material (CRIM) status to inform treatment decisions. CRIM status can be determined using a leucocyte assay or predicted from GAA molecular genetics.36 37 CRIM-positive patients have detectable GAA protein irrespective of GAA activity and may have a lower risk of developing antidrug antibodies compared with CRIM-negative patients who have no detectable GAA protein on Western blotting and who, therefore, will not have had natural thymic tolerisation to the GAA protein epitopes.13 38 Antidrug antibodies reduce the efficacy of enzyme replacement therapies (ERTs) by inhibiting enzyme uptake or catalytic activity, leading to a poorer prognosis in CRIM-negative patients, which necessitates immunomodulation with immune tolerance induction.39 Notably, a subset of CRIM-positive patients have been shown to develop high titres of antirecombinant human (recombinant human alpha-glucosidase) antibodies, which correlate with clinical decline.39 Multidisciplinary management General clinical management principles On reaching a diagnosis, it is recommended that patients are referred to specialised services with experience in the management of patients with Pompe disease. It is important for patient care to be overseen by an MDT due to the complex, multisystem nature and high burden of Pompe disease. Statements relating to the specialties that should be involved are presented in box 2, and those relating to treatment and management strategies are presented in box 3. Ideally, a physician familiar with the needs of patients with Pompe disease would coordinate the team and support patient and caregiver education. MDT members required for optimum patient management IOPD For patients with IOPD, the MDT must include a paediatric cardiologist, a metabolic paediatrician, a clinical nurse specialist, a paediatric respiratory specialist, a paediatric neurologist, a paediatric physiotherapist, a specialist dietitian, a speech and language therapist and a pharmacist. LOPD At minimum, the MDT should include a metabolic specialist, a specialist nurse for continued care, a respiratory specialist or pulmonologist (if there is evidence of respiratory involvement), a neurologist, a physiotherapist, a dietitian and a pharmacist. Additional MDT considerations Other MDT members who can be consulted when the need arises include a gastroenterologist to support feeding needs or to manage gastric motility symptoms, a urologist, an orthopaedist, an audiologist or ENT specialist in the case of hearing loss, an ophthalmologist in the case of ptosis, a dentist, a wheelchair and seating specialist, incontinence services and pain management team. An occupational therapist should be available when needed to advise on home and school aides and adaptations, driving and other aspects of daily living. Referrals to psychological support services for patients and parents are recommended as early as possible while maintaining vigilance for emerging mental health problems. Community and palliative care options should be considered. ENT, ear, nose and throat; IOPD, infantile-onset Pompe disease; LOPD, late-onset Pompe disease; MDT, multidisciplinary team. Assessing treatment effect and ongoing monitoring Multidisciplinary monitoring Ongoing monitoring should ideally be undertaken by a multidisciplinary team Laboratory parameters that may be used in monitoring include CK levels. Hex4 has been proposed as a useful measure in IOPD but there is no consensus on their use in clinics. In IOPD, anti-rhGAA antibody levels should be monitored regularly during treatment and after ERT switching, regardless of CRIM status. Muscle function should be evaluated using a combination of assessments mentioned above (6MWT, time to walk 10 m, TUG, NSAD, Bayley Scales of Infant and Toddler Development), where appropriate and as determined by the multidisciplinary team. In IOPD, cardiac assessment should be performed initially at the recommendation of cardiology specialists, but should be continued at least yearly even after hypertrophic resolution, due to ongoing risks of conduction problems and/or immunological-mediated failure of ERT. In LOPD, a baseline echocardiogram and ECG shuld be conducted. Ssubsequent monitoring should be tailored to the patient’s needs. Lung function (spirometry) and respiratory muscle function assessments (preferably supine and sitting along with ear lobe gases) should be carried out at least yearly where feasible, depending on patients’ age, abilities and symptom severity. In IOPD, cranial MRI should be considered at the onset of formal schooling, change to secondary school and prior to transition to adult medicine if anaesthetic risk is acceptable. Similarly, appropriate formal cognitive assessments should be considered if there are either clinical concerns or progressive leukodystrophy is found on scanning. Regarding frequency of reviews, these may change according to patients’ needs. Patients with IOPD should be evaluated regularly at treatment initiation, and follow-up evaluations should be carried out every 3–6 months. Patients with LOPD should be evaluated frequently from treatment initiation and every 6–12 months thereafter once stable, unless there is an acute deterioration. Signs of acute deterioration may include symptoms suggestive of carbon dioxide retention (morning headache, fatigue), frequent falls or significant drop in motor function and/or activities of daily living. Asymptomatic patients may have less frequent (eg, annual) reviews and their evaluations should be focused on muscle function, cardiac function, lung function and activities of daily living. Patients should have access to clinicians in case of deterioration between reviews. Monitoring tools Biochemical markers such as CK are informative when used in combination with other measures but do not always correlate with clinical severity. There is scope to develop more disease-specific outcome measure tools, especially in IOPD where there are no precise tools to measure cognitive decline or improvements in Gower’s manoeuvre, for example, using cranial MRI referred to above. There is a need for a standardised ‘tool box’ of muscle assessments across treatment centres that can capture clinically relevant outcomes and have scope for ambulatory and non-ambulatory patients. Patient care across centres in the UK To optimise patient care across the UK, guidelines should be standardised regarding baseline assessments and ongoing monitoring. 6MWT, 6 min walk test; CK, creatine kinase; CRIM, cross-reactive immunological material; ERT, enzyme replacement therapy; Hex4, glucotetrasaccharide; IOPD, infantile-onset Pompe disease; LOPD, late-onset Pompe disease; NSAD, North Star Assessment for limb-girdle type muscular dystrophies; rhGAA, recombinant human alpha-glucosidase; TUG, time up and go. ERT is the mainstay therapeutic approach in Pompe disease, leading to improvements in cardiac symptoms and skeletal muscle function in IOPD, resulting in motor and respiratory improvement that leads to prolonged survival.14 ERT also results in improvements in respiratory function and skeletal muscles in LOPD.10 Comprehensive baseline measurements of the various clinical manifestations are key to monitoring treatment effect over time. For IOPD, treatment should be started at the appropriate dose as early as feasible. In LOPD, locally approved ERT should be initiated where clinically indicated in patients showing signs of respiratory involvement or muscle weakness.31 We note that treatment initiation might not be suitable in patients with advanced disease. Patient and family counselling in relation to expected outcomes from ERT is important in both IOPD and LOPD patients. Patients should be observed for any allergic reaction or anaphylaxis and appropriate medical support should be available. IOPD clinical management Cardiac manifestations management Glycogen accumulation in cardiomyocytes and the cardiac conduction system leads to severe ventricular hypertrophy with outflow tract obstruction that if not managed may result in cardiac failure or death. Failure to thrive can be a consequence of cardiac failure.14 15 Arrhythmias can also be present in patients with IOPD as a consequence of the structural cardiopathy. ERT is highly effective in reducing the size of the left ventricle and controlling cardiac symptoms and should be started as soon as possible in all patients. Other cardiac-supportive medications may also be indicated if there are signs of cardiac failure and used in parallel with ERT, such as beta-blockers. Changes in the heart structure should be followed up carefully using echocardiography and ECG periodically.15 18 Considerations for respiratory manifestations Respiratory management depends on patients’ individual symptoms. Progressive respiratory muscle and diaphragmatic weakness lead to respiratory insufficiency/respiratory failure and can result in sleep-disordered breathing.9 Initial assessment of an infant with IOPD will be based on clinical assessment of respiratory sufficiency, oxygen requirement determined by continuous pulse oximetry and requirement for ventilatory support. Use of polysomnography ‘sleep studies’ is important in the initial assessment. For those infants who survive to childhood, use of more formal respiratory measures can be introduced when the child is able to perform the required tests such as spirometry, inspiratory and sniff inspiratory pressures, crying vital capacity when possible and peak cough flow.14 Other measurements include negative inspiratory flow measurements to assess inspiratory muscle strength, and capnography or venous bicarbonate or partial pressure of carbon dioxide to measure gas exchange. Pulmonologists may recommend measures to clear airways, including bronchodilators and assisted coughing manoeuvres.8 Depending on disease severity, use of ventilatory support may be required.10 Management of musculoskeletal symptoms Due to the extensive generalised muscle weakness seen in IOPD, patients’ muscle strength and function need thorough evaluation at baseline and regularly (frequency can be determined by the clinical team) after starting treatment. Infants with IOPD are usually globally hypotonic; the severity of weakness should be determined using age-appropriate tests, which may include Alberta Infant Motor Scales, North Star Assessment for Limb Girdle Type Muscular Dystrophies, Neuromuscular Gross Motor Outcome, Peabody Developmental Motor Scale or Bayley Scales of Infant and Toddler Development.8 40 Management goals should include rehabilitative and preventative measures that preserve motor function. LOPD clinical management Musculoskeletal evaluation and monitoring Patients should be seen in clinics at least once every year to discuss symptoms, changes in disease progression and to evaluate muscle function. Muscle weakness should be evaluated at baseline and in subsequent reviews to monitor treatment effect, using the assessments recommended in box 3. Even though there is no set of standardised tests performed in patients, tests such as the 6- minute walk test or assessment of muscle strength using manual muscle testing are commonly used in clinics. Complications can include fractures, osteopenia and osteoporosis.41 Assessments should account for patients’ age, ambulatory status and degree of disability, with management strategies aiming to preserve and strengthen motor function. Respiratory assessments Patients with Pompe disease should be evaluated for symptoms of respiratory insufficiency and signs of ventilatory failure, including dyspnoea, blood gas abnormalities, impaired cough, morning headaches, daytime somnolence and exercise tolerance. Pulmonary function tests using spirometry are recommended and can aid in diagnosing respiratory insufficiency. Other pulmonary tests also include sniff nasal inspiratory pressure, capnography and peak cough flow.42 A drop in forced vital capacity (FVC) from sitting to supine, which suggests diaphragmatic weakness,43 reduced maximal inspiratory pressure and maximal expiratory pressure and ear lobe gases are useful parameters in evaluating patients with LOPD.17 Diaphragm weakness can also be evaluated using MRI or ultrasound. Routine sleep studies using polysomnography, pulse oximetry and non-invasive positive pressure ventilation should also be conducted to monitor respiratory involvement and investigate possible sleep apnoea.8 42 Cough assist should be offered where appropriate and the use of ventilatory support may be required. Cardiological involvement management Cardiac hypertrophy is very rare in patients with LOPD but arrhythmias have been reported with varying frequencies across study cohorts.17 Echocardiography and ECG at baseline and subsequent follow-ups can be used to ascertain cardiac involvement and plan intervention. Evaluations of impact of Pompe disease on quality of life Pompe disease often results in significant morbidity and disability that negatively impact patients’ HRQoL. There are quantitative tools to measure these impacts, such as the generic 36-Item Short Form Survey.44 The Rasch-Built Pompe-Specific Activity scale (R-PAct) measures the effects of Pompe disease specifically on patients’ daily living and social lives.45 R-PAct has been validated and used in clinical trials and routine clinical practice.45 While R-PAct is tailored to assess the experiences of patients with Pompe disease, it does not cover some aspects of the disease, such as respiratory symptoms.44 45 Moreover, the Rotterdam Handicap Scale can be used to assess independence and participation in activities of daily living.46 Other Pompe disease-specific tools are the Pompe Disease Symptom Scale and Impact Scale that assess symptom severity and their effect on mood and ability to perform activities, respectively.47 Additional scales that can be used to monitor symptoms include the Fatigue Severity Scale and Patient-Reported Outcomes Measurement Information System Fatigue.18 48 Perception of exertion can be assessed using the Borg Rating of Perceived Exertion Scale.49 Pain can be evaluated using the Visual Analog Scale.50 While these tools are not specific for patients with Pompe disease, they can aid with monitoring the progression of these symptoms common in Pompe disease. Overall management should be comprehensive, account for individual patient needs, disease presentation and support with improving patients’ HRQoL.9 Following on from the evaluations and recommendations presented in box 3, patients should be assessed for stability or deterioration using similar tools. Recommendations on diet and exercise Recommendations on nutrition and exercise are presented in box 4. Feeding and/or swallowing difficulties can cause dietary deficiencies while insufficient protein intake can result in endogenous protein breakdown.8 Muscle strength has been shown to improve on a high-protein, low-carbohydrate diet in adult patients with LOPD under chronic ERT treatment.51 52 A diet of 25%–30% protein, 30%–35% carbohydrate and 35%–40% fat combined with strength and aerobic exercises was shown to improve FVC and quality of life.52 These findings need to be confirmed in larger cohorts. Until strong evidence of specific dietary regimens becomes available, patients should be directed to adopt a normal healthy diet and maintain ideal body weight. Dysphagia evaluations and feeding support must be available if needed and may be required in some patients. Recommendations on diet and exercise Patients’ diets should be managed under the direction of a dietitian to ensure a healthy, varied diet that is tailored to the patient’s needs and to maintain ideal body weight. In IOPD, patients should be monitored by a paediatric dietitian with expertise in IOPD, especially in cases where patients are supported by enteral feeding.Baseline and follow-up monitoring of swallowing efficacy and safety is required, in addition to vitamin D and calcium levels, with support from a speech and language therapist where necessary. In IOPD, patients should be monitored by a paediatric dietitian with expertise in IOPD, especially in cases where patients are supported by enteral feeding. Baseline and follow-up monitoring of swallowing efficacy and safety is required, in addition to vitamin D and calcium levels, with support from a speech and language therapist where necessary. Baseline and follow-up monitoring of swallowing efficacy and safety is required, in addition to vitamin D and calcium levels, with support from a speech and language therapist where necessary. Special consideration should be given to vitamin D intake and bone density should be investigated where relevant. Regarding exercise, a specialist physiotherapist should be consulted. Aerobic and strength exercises should be recommended and tailored to patients’ needs. IOPD, infantile-onset Pompe disease. Fracture secondary to osteoporosis has been reported in patients with Pompe disease.19 Therefore, we recommend monitoring bone mineral density and for patients to take vitamin D and calcium supplements where needed. Bone mineral density can be monitored using dual-energy X-ray absorptiometry. Additionally, while there are no specific guidelines on the types of muscle strengthening exercises recommended for patients, there is some evidence that submaximal aerobic exercise, resistance training and breathing exercises, where possible, can increase muscle strength and improve glycogen clearance, though further studies are needed to corroborate these findings.9 A physiotherapist with experience in Pompe disease should be consulted to draft an appropriate exercise programme following musculoskeletal assessment. Other clinical observations that may require additional monitoring include: evidence of peripheral neuropathy, hearing loss, impact on bowel and bladder functions, musculoskeletal pain and any other emerging manifestation should be explored on each visit. Patient review optimisation There is a need to optimise and standardise patient reviews across treatment centres to minimise burden and reduce bias. Patients may find consecutive testing days and associated travel tiring. Single assessments can be unrepresentative and provide insufficient detail about disease progression or stabilisation. This can be mitigated by effective coordination between specialists and primary care providers, offering virtual consultations between visits and making use of remote monitoring tools, such as smart watches to track step count and sleep activity. Our recommendations are listed in box 5. Patient and caregiver education during clinics and the provision of educational resources can also contribute to improving disease understanding and consequently improve reporting of symptoms. Conclusion This consensus aims to support clinicians in the UK with diagnosis, management and monitoring of patients with Pompe disease. There is a variability in patient care among centres that the guidance we present is intended to help address, by identifying optimal approaches that can be adopted more consistently. We hope it can also raise awareness among, and be of value to, healthcare professionals who are inexperienced in managing patients with Pompe disease. Clinical judgement should, of course, be used in the application of this guidance in practice. Limitations of this work include the relatively small number of experts involved. There is scope for expanding on these guidelines, including defined clinical parameters from a wider range of medical specialties. A survey of treatment approaches across all UK centres could also be conducted to identify areas of dissimilarity and help develop further guidelines to standardise care pathways. Supplementary material Acknowledgements The authors would like to thank Tasabeeh Mohamed and Colin Glen from Lucid Group Communications Ltd, London, United Kingdom, for providing medical writing support. Medical writing support was funded by Sanofi in accordance with Good Publication Practice (GPP3) guidelines. Footnotes Funding: Sanofi funded the expert meeting. The authors received no payment from Sanofi related to the development of this publication. Sanofi had the opportunity to review the publication; however, the authors remain responsible for all content, editorial decisions and the decision to submit the manuscript. Sanofi provided funding to Lucid Group Ltd., for support in writing and editing this manuscript under the direction of all authors. Provenance and peer review: Not commissioned; externally peer-reviewed. Patient consent for publication: Not applicable. Ethics approval: Not applicable. References Associated Data Supplementary Materials